Troutman Pepper Locke Advises Arkstone Medical Solutions in Sale to ARCHIMED

NEW YORK – Troutman Pepper Locke advised Arkstone Medical Solutions (Arkstone), an innovative biotechnology company democratizing infectious disease proficiency and fighting antimicrobial resistance, in its majority stake sale to ARCHIMED, a leading private equity firm specializing in the health care sector. For more information, see the press release.

The transaction marks a pivotal moment in Arkstone’s growth trajectory, positioning the company to expand its global footprint, deepen its research and development capabilities, and bring its precision-guided technology to more clinicians around the world. Backed by ARCHIMED’s capital, extensive health care experience, and international reach, Arkstone is poised to scale its impact on the global fight against antimicrobial resistance, one of the most urgent public health threats of our time.

The Troutman Pepper Locke team that advised Arkstone was led by Steven Khadavi, Joe Kadlec, Andrew Hughes, Celia Marcum, Jack Taylor, and Taylor Williams.

Consistently recognized as a top-tier practice, Troutman Pepper Locke’s corporate attorneys regularly handle strategic deals for Fortune 100 corporations and middle market transactions for private equity clients. Core areas of service include mergers and acquisitions, corporate finance, corporate governance, securities laws compliance, capital markets transactions, and other significant domestic and cross-border transactions, as well as general corporate counseling.

Troutman Pepper Locke

Troutman Pepper Locke helps clients solve complex legal challenges and achieve their business goals in an ever-changing global economy. With more than 1,600 attorneys in 30+ offices, the firm serves clients in all major industry sectors, with particular depth in energy, financial services, health care and life sciences, insurance and reinsurance, private equity, and real estate. Learn more at troutman.com.